Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 4Other solid neoplasm 3Gastrointestinal 3Myeloid 2Dermatologic 2Tumor-Agnostic 1Other neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Lymphoma 1

Interventions

Rituximab 1371Cyclophosphamide 1296Vincristine 662Doxorubicin 583Etoposide 525Prednisone 504Cytarabine 481fludarabine 461Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 254ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 227Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infusions, Intravenous × Lymphoid × Clear all
NCT04477772 2024-05-16

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Completed
71 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡